Outcomes of Active Surveillance for Japanese Prostate Cancer Patients (PRIAS-JAPAN Study)

What is it about?

The PRIAS-JAPAN study is a prospective observational study for Japanese patients with prostate cancer. The study initially included low-risk patients with a prostate-specific antigen (PSA) density (PSAD) <0.2 and ≤2 positive biopsy cores. The eligibility criteria were expanded over time, and as of February 2024, a total of 1302 patients were enrolled in active surveillance (AS). The pathological reclassification rate for biopsies was approximately 30%, and the acceptance rate for re-biopsy decreased over time. The study found that metastasis occurred in six patients, but only one death from prostate cancer was recorded.

Featured Image

Why is it important?

The research is important because it provides valuable insights into the outcomes of active surveillance for prostate cancer patients in Japan. This study helps to address the lack of evidence specific to the Japanese population and provides a better understanding of the effectiveness and safety of active surveillance as a management strategy for low-risk prostate cancer patients. Key Takeaways: 1. The study involved 1302 patients in the Prostate Cancer Research International: Active Surveillance (PRIAS)-JAPAN study. 2. The inclusion criteria were expanded over time, allowing for more patients to be eligible for active surveillance.\n 3. Approximately 30% of patients experienced pathological reclassification at each scheduled biopsy, and the acceptance rate for re-biopsy decreased over time. 4. PRIAS-JAPAN shows the results of an AS study conducted in men of Mongolian descent, a group that has not been adequately studied. 5. The study highlights the need for further research and education on the benefits and risks of active surveillance for prostate cancer patients in Japan.